市场调查报告书
商品编码
1370384
蛋白质治疗市场:2023-2028 年全球产业趋势、份额、规模、成长、机会与预测Protein Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年全球蛋白质治疗市场规模达3,227亿美元。展望未来,IMARC集团预计到2028年市场规模将达到4,870亿美元,2023-2028年复合年增长率(CAGR)为7%。癌症、糖尿病、心血管疾病和自体免疫疾病等慢性疾病的盛行率不断上升,蛋白质工程技术的快速进步,生物製药行业的不断扩大以及产品在不同治疗领域的广泛应用是推动市场发展的一些因素。
蛋白质疗法是一类利用蛋白质或胜肽来预防、控製或治癒疾病的医学治疗方法。这些疗法旨在针对体内的特定分子或途径,提供高度针对性的治疗方法。他们为多种疾病提供创新的解决方案,包括癌症、自体免疫疾病、遗传性疾病等。它们可以来自天然来源,也可以透过重组 DNA 技术生产,从而可以开发高度特异性和有效的疗法。这些治疗性蛋白质可以采取多种形式,包括单株抗体、生长因子、酵素和细胞激素。它们与体内的特定受体或分子相互作用,调节细胞过程,抑製或刺激免疫反应,或直接针对致病因子。蛋白质疗法的优点在于其高特异性、效力和低毒性。与传统的小分子药物相比,它们通常具有更高的疗效和更少的副作用。他们大大推进了医学领域的发展,提供了新颖的治疗选择并改善了各种疾病的患者治疗结果。
全球市场的主要驱动力是对个人化医疗的日益关注。与此一致的是,不断增加的研发活动和不断扩大的医疗基础设施正在为市场做出巨大贡献。此外,製造流程的进步预计将推动市场的发展。除此之外,基因工程、蛋白质合成和生产技术的突破提高了蛋白质治疗的效率和有效性,对市场产生了积极影响。此外,癌症、糖尿病、心血管疾病和自体免疫疾病等慢性疾病的日益普及正在催化市场。此外,蛋白质疗法在肿瘤学中的广泛应用正在刺激市场。此外,药物输送系统的快速创新改善了蛋白质治疗药物的输送,提高了其疗效和患者依从性。缓释製剂、奈米颗粒和标靶药物递送系统等新型递送方法可透过增加蛋白质药物的治疗潜力来推动市场成长。
不断增加的生物製药研发投资
由于蛋白质药物具有高特异性、有效性和标靶性,生物製药公司和研究机构越来越关注其开发。生物製药领域研发投资的增加正在推动蛋白质疗法的进步。这些投资支持与蛋白质工程、药物发现和配方优化相关的研究活动,从而开发新型和改进的蛋白质疗法。此外,分配给研发的大量资金使研究人员能够探索新的治疗靶点,优化蛋白质结构以增强活性,并进行广泛的临床前和临床试验。这些努力透过引入针对各种疾病的创新疗法,有助于扩大市场。此外,不断增长的研发投资有助于扩大蛋白质疗法的生产工艺,使其更容易获得且更具成本效益。这使得蛋白质药物的商业化和市场渗透率得到提高。
生物相似药的扩展
生物相似药市场的扩张对市场做出了重大贡献。生物相似药是与已核准的参考蛋白治疗药物高度相似的生物药物。随着几种重磅生物製剂的专利到期,生物相似药市场正在迅速扩大。生物相似药的出现为昂贵的蛋白质疗法提供了具有成本效益的替代品,使患者和医疗保健系统更容易获得它们。负担能力的提高使患者能够获得必要的治疗,从而推动市场成长。此外,生物相似药的引入促进了市场竞争。竞争导致价格下降,鼓励市场扩张,并为生物相似药製造商和参考蛋白治疗公司创造创新和改进产品的机会。此外,生物相似药的监管框架和指南已经更加完善和简化,为其开发和批准提供了明确的途径。这给医疗保健界注入了信心,并导致生物相似药的采用增加。随着生物相似药市场的扩大,它刺激了蛋白质疗法的进一步研究和开发工作。製造商努力开发更先进和差异化的生物相似药,为市场创造了积极的前景。
人口老化加剧
人口老化的加剧对市场有正面影响。随着全球人口老化,阿兹海默症、帕金森氏症、黄斑部病变和骨质疏鬆症等与年龄相关的疾病和病症的盛行率更高。蛋白质疗法正在开发和利用,以解决老龄化人口面临的这些特定健康挑战。此外,蛋白质疗法为与年龄相关的疾病提供了有针对性的治疗选择,与传统疗法相比,可以提高疗效并减少副作用。它们可以针对特定的分子途径并解决这些疾病的潜在机制,从而改善患者的治疗结果和生活品质。此外,老龄化人口不断增长的产品需求正在推动市场成长。製药公司和研究机构正在投资开发新型蛋白质疗法,以满足这一人群的特定需求。此外,日益增长的老龄化人口为蛋白质治疗创造了更大的市场,促使製造商扩大产品组合併增加产量。这反过来又导致蛋白质疗法的更广泛应用并进一步推动市场成长。
IMARC Group 提供了全球蛋白质治疗市场报告各细分市场主要趋势的分析,以及 2023-2028 年全球、区域和国家层面的预测。我们的报告根据产品、治疗领域和功能对市场进行了分类。
单株抗体 (mAb)
人类胰岛素
促红血球生成素
凝血因子
融合蛋白
其他的
单株抗体 (mAb) 主导市场
该报告根据产品提供了详细的市场细分和分析。这包括单株抗体 (mAb)、人类胰岛素、促红血球生成素、凝血因子、融合蛋白等。根据该报告,单株抗体(mAb)代表了最大的部分。
单株抗体 (mAb) 广泛用于治疗癌症、自体免疫疾病和发炎性疾病。这些疾病的日益普遍,加上抗体工程和生产技术的进步,推动了对单株抗体的需求并促进了市场的成长。
另一方面,人类胰岛素是治疗糖尿病的重要蛋白质疗法。随着全球糖尿病发生率的上升,对胰岛素和胰岛素类似物的需求不断增加,导致该领域的市场成长。此外,促红血球生成素(EPO)是另一种刺激红血球生成的重要治疗蛋白。它用于治疗贫血,特别是患有慢性肾臟病和接受化疗的癌症患者。需要 EPO 治疗的患者群体不断扩大正在推动这一领域的成长。
除此之外,凝血因子是血液凝固所必需的蛋白质。它们用于治疗血友病等出血性疾病。对血友病的认识、诊断和治疗的不断增长推动了对凝血因子的需求并为市场做出了贡献。此外,结合两个或多个功能性蛋白结构域的融合蛋白在创新疗法的开发中受到了极大的关注。他们为包括癌症和自体免疫疾病在内的各种疾病提供独特的治疗方法,从而推动了该领域的市场。
代谢紊乱
免疫系统疾病
血液系统疾病
癌症
荷尔蒙失调
遗传性疾病
其他的
代谢紊乱占据最大的市场份额
报告还提供了基于治疗领域的详细市场细分和分析。这包括代谢失调、免疫失调、血液失调、癌症、荷尔蒙失调、遗传失调等。报告称,代谢紊乱占据了最大的市场份额。
代谢紊乱包括糖尿病、肥胖症和高胆固醇血症等病症。蛋白质疗法,例如用于糖尿病管理的胰岛素,对于治疗和控制这些疾病至关重要。代谢紊乱的盛行率不断上升,加上对有针对性的有效治疗的需求不断增加,正在推动该领域市场的成长。
相反,免疫性疾病,包括自体免疫疾病和发炎性疾病,代表了蛋白质疗法的另一个重要治疗领域。单株抗体和其他以蛋白质为基础的药物可调节免疫系统并针对特定的疾病途径。免疫系统疾病的发生率不断上升,以及针对这些疾病的批准的蛋白质疗法范围不断扩大,正在推动市场的发展。
此外,癌症仍然是市场的主要驱动力之一。基于蛋白质的疗法,包括单株抗体、抗体药物偶联物和免疫检查点抑制剂,已经彻底改变了癌症治疗。全球癌症发生率不断上升,加上标靶疗法和免疫疗法的发展,正在推动肿瘤学市场的成长。
酶促和调节活性
特别目标活动
疫苗
蛋白质诊断
报告还根据功能对市场进行了详细的细分和分析。这包括酶促和调节活性、特殊靶向活性、疫苗和蛋白质诊断。
具有酶活性和调节活性的蛋白质疗法对于调节生物过程和代谢途径至关重要。这些蛋白质可作为酵素、受体或信号分子,为各种疾病提供治疗益处。具有特定酶或调节功能的新型蛋白质疗法的开发推动了该领域的市场成长。
此外,特殊标靶活性是指针对某些细胞、组织或分子标靶的蛋白质治疗。单株抗体和抗体药物偶联物是具有特殊标靶活性的蛋白质疗法的例子。它们可以精确识别并结合特定分子或细胞,提供高度针对性的治疗。癌症和自体免疫疾病等疾病对标靶治疗的需求不断增长,推动了该领域蛋白质疗法的成长。
此外,疫苗是市场的另一个重要部分。基于蛋白质的疫苗利用特定的蛋白质或胜肽来刺激免疫反应并赋予针对传染病的免疫力。全球对疫苗接种计划的关注、新传染病的出现以及对改进疫苗技术的需求推动了该领域的市场成长。
此外,蛋白质诊断涉及使用蛋白质或基于蛋白质的测定来进行诊断。这些诊断可以检测与疾病相关的特定蛋白质或生物标记物,有助于早期检测、疾病监测和个人化治疗。对准确可靠的诊断工具的需求不断增长,推动了蛋白质诊断的成长,并对整个市场做出了贡献。
北美洲
美国
加拿大
亚太地区
中国
日本
印度
韩国
澳洲
印尼
其他的
欧洲
德国
法国
英国
义大利
西班牙
俄罗斯
其他的
拉丁美洲
巴西
墨西哥
其他的
中东和非洲
北美表现出明显的主导地位,占据最大的蛋白质治疗市场份额
该报告还对所有主要区域市场进行了全面分析,其中包括北美(美国和加拿大);亚太地区(中国、日本、印度、韩国、澳洲、印尼等);欧洲(德国、法国、英国、义大利、西班牙、俄罗斯等);拉丁美洲(巴西、墨西哥等);以及中东和非洲。
北美,尤其是美国,占有重要的市场占有率。该地区受益于先进的医疗基础设施、强大的生物製药公司以及强劲的研发活动。主要参与者的存在和对蛋白质治疗研究的广泛投资有助于北美市场的成长。此外,慢性病盛行率高、人口老化程度高以及有利的报销政策进一步推动了该地区的市场。
另一方面,亚太地区正成为一个快速成长的市场。该地区人口基数大,医疗支出不断增加,慢性病盛行率不断上升。中国、日本和印度等国家的生物製药产业和研发投资都在大幅成长。此外,对个人化医疗的认识不断增强,以及对具有成本效益的治疗方案的需求不断增长,正在推动蛋白质疗法在亚太地区的采用。
顶尖公司正在大力投资科学研究,以确定新的治疗标靶并开发具有更高功效和安全性的蛋白质药物。他们利用蛋白质工程、分子生物学和生物技术专业知识来设计和优化治疗性蛋白质。此外,这些公司与学术机构、研究组织和其他製药公司建立策略合作,以获取新技术、扩大管道并加速开发。合作促进知识、资源和专业知识的交流,促进创新并推动市场发展。此外,成功的商业化策略在推动市场成长方面发挥着至关重要的作用。这些公司采用强大的行销和销售努力,向世界各地的医疗保健提供者和患者推广和分销其产品。他们进行广泛的临床试验,产生令人信服的临床资料,并获得监管部门的批准以确保市场准入。此外,顶尖公司不断投资于製造能力和品质控制系统,以满足不断增长的需求并确保其产品的持续供应。这种对卓越製造的承诺帮助他们满足患者、医疗保健提供者和付款人的需求,进一步推动市场成长。
安进公司
雅培实验室
艾伯维公司
百特国际公司
百健公司
Csl Behring LLC(CSL 有限公司)
礼来公司
F.霍夫曼-拉罗氏股份公司(罗氏控股股份公司)
强生公司
默克公司
诺和诺德公司 (Novo Holdings A/S)
辉瑞公司
2020 年,安进公司 (Amgen Inc.) 与 Adaptive Biotechnologies 合作,开发并商业化针对 SARS-CoV-2(引起 COVID-19 的病毒)的完全人类中和抗体。
2021 年,雅培实验室 (Abbott Laboratories) 的 Tendyne 经导管二尖瓣置换 (TMVR) 系统获得 FDA 批准,这是一种针对严重二尖瓣逆流患者的微创疗法。
2020 年,艾伯维公司 (AbbVie Inc.) 收购了艾尔建 (Allergan),这是一家以其美容和治疗产品组合而闻名的製药公司,其中包括 Botox。
The global protein therapeutics market size reached US$ 322.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 487.0 Billion by 2028, exhibiting a growth rate (CAGR) of 7% during 2023-2028. The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders, the rapid technological advancements in protein engineering, the expanding biopharmaceutical industry, and the widespread product applications in diverse therapeutic areas are some factors propelling the market.
Protein therapeutics is a class of medical treatments utilizing proteins or peptides to prevent, manage, or cure diseases. These therapeutics are designed to target specific molecules or pathways within the body, providing a highly targeted approach to treatment. They offer innovative solutions for a wide range of conditions, including cancer, autoimmune disorders, genetic diseases, and more. They can be derived from natural sources or produced through recombinant DNA technology, allowing for the development of highly specific and potent therapies. These therapeutic proteins can take various forms, including monoclonal antibodies, growth factors, enzymes, and cytokines. They interact with specific receptors or molecules in the body, modulating cellular processes, inhibiting or stimulating immune responses, or directly targeting disease-causing agents. The advantages of protein therapeutics lie in their high specificity, potency, and low toxicity. They often offer improved efficacy and fewer side effects than traditional small-molecule drugs. They have significantly advanced the field of medicine, providing novel treatment options and improving patient outcomes across various diseases.
The global market is majorly driven by the increasing focus on personalized medicine. In line with this, the rising research and development activities and the expanding healthcare infrastructure are significantly contributing to the market. Furthermore, the advancements in manufacturing processes are expected to fuel the market. Apart from this, the breakthroughs in genetic engineering, protein synthesis, and production technologies have enhanced the efficiency and effectiveness of protein therapeutics, positively influencing the market. Moreover, the growing prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and autoimmune diseases is catalyzing the market. Besides, the widespread applications of protein therapeutics in oncology are stimulating the market. Additionally, the rapid innovations in drug delivery systems have improved the delivery of protein therapeutics, enhancing their efficacy and patient compliance. Novel delivery methods such as sustained-release formulations, nanoparticles, and targeted drug delivery systems are driving the market growth by increasing the therapeutic potential of protein drugs.
Growing biopharmaceutical research and development investments
Biopharmaceutical companies and research institutions are increasingly focusing on the development of protein-based drugs due to their high specificity, efficacy, and targetability. The rise in R&D investments in the biopharmaceutical sector is fueling advancements in protein therapeutics. These investments support research activities related to protein engineering, drug discovery, and formulation optimization, leading to the development of novel and improved protein therapeutics. Furthermore, the substantial funds allocated to R&D enable researchers to explore new therapeutic targets, optimize protein structures for enhanced activity, and conduct extensive preclinical and clinical trials. These efforts contribute to the expansion of the market by introducing innovative treatments for various diseases. Moreover, the growing R&D investments facilitate the scaling-up of production processes for protein therapeutics, making them more accessible and cost-effective. This enables increased commercialization and market penetration of protein-based drugs.
Expansion of biosimilars
The expansion of the biosimilars market is significantly contributing to the market. Biosimilars are biologic drugs that are highly similar to approved reference protein therapeutics. As patents for several blockbuster biologics expire, the market for biosimilars is expanding rapidly. The availability of biosimilars provides cost-effective alternatives to expensive protein therapeutics, making them more accessible to patients and healthcare systems. This increased affordability enhances patient access to necessary treatments, driving market growth. Furthermore, the introduction of biosimilars fosters competition in the market. Competition leads to price reductions, encouraging market expansion and creating opportunities for biosimilar manufacturers and reference protein therapeutics companies to innovate and improve their products. Moreover, the regulatory frameworks and guidelines for biosimilars have become more established and streamlined, providing a clear pathway for their development and approval. This has instilled confidence in the healthcare community and resulted in increased biosimilar adoption. As the biosimilars market expands, it stimulates further research and development efforts in protein therapeutics. Manufacturers strive to develop more advanced and differentiated biosimilars, creating a positive outlook for the market.
Rising aging population
The rising aging population is positively influencing the market. As the global population ages, there is a higher prevalence of age-related diseases and conditions such as Alzheimer's disease, Parkinson's disease, macular degeneration, and osteoporosis. Protein therapeutics are being developed and utilized to address these specific health challenges the aging population faces. Furthermore, protein therapeutics offer targeted treatment options for age-related diseases, providing improved efficacy and reduced side effects as compared to traditional therapies. They can target specific molecular pathways and address the underlying mechanisms of these diseases, thereby improving patient outcomes and quality of life. Moreover, the increasing product demand among the aging population is driving market growth. Pharmaceutical companies and research institutions are investing in the development of novel protein therapeutics to meet the specific needs of this demographic. Additionally, the growing aging population creates a larger market for protein therapeutics, prompting manufacturers to expand their product portfolios and increase production. This, in turn, leads to a wider availability of protein therapeutics and further drives market growth.
IMARC Group provides an analysis of the key trends in each segment of the global protein therapeutics market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on product, therapy area, and function.
Monoclonal Antibodies (mAbs)
Human Insulin
Erythropoietin
Clotting Factors
Fusion Protein
Others
Monoclonal Antibodies (mAbs) dominates the market
The report has provided a detailed breakup and analysis of the market based on product. This includes monoclonal antibodies (mAbs), human insulin, erythropoietin, clotting factors, fusion protein, and others. According to the report, monoclonal antibodies (mAbs) represented the largest segment.
Monoclonal antibodies (mAbs) are extensively used to treat cancer, autoimmune disorders, and inflammatory diseases. The increasing prevalence of these conditions, coupled with advancements in antibody engineering and production technologies, drives the demand for mAbs and contributes to the market growth.
On the other hand, human insulin is a vital protein therapeutic for managing diabetes. With the rising incidence of diabetes worldwide, the demand for insulin and insulin analogs is increasing, leading to market growth in this segment. Moreover, erythropoietin (EPO) is another important therapeutic protein stimulating red blood cell production. It is used to treat anemia, particularly in patients with chronic kidney disease and cancer undergoing chemotherapy. The expanding patient pool requiring EPO therapy is driving the growth of this segment.
Besides this, the clotting factors are proteins essential for blood clotting. They are used to manage bleeding disorders such as hemophilia. The growing awareness, diagnosis, and treatment of hemophilia fuel the demand for clotting factors and contribute to the market. In addition, fusion proteins, which combine two or more functional protein domains, have gained significant attention in the development of innovative therapeutics. They offer unique treatment approaches for various diseases, including cancer and autoimmune disorders, thus driving the market in this segment.
Metabolic Disorders
Immunological Disorders
Hematological Disorders
Cancer
Hormonal Disorders
Genetic Disorders
Others
Metabolic Disorders holds the largest share of the market
A detailed breakup and analysis of the market based on the therapy area have also been provided in the report. This includes metabolic disorders, immunological disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others. According to the report, metabolic disorders accounted for the largest market share.
Metabolic disorders encompass conditions such as diabetes, obesity, and hypercholesterolemia. Protein therapeutics, such as insulin for diabetes management, are crucial in treating and controlling these disorders. The rising prevalence of metabolic disorders, coupled with the increasing demand for targeted and effective treatments, is driving the growth of the market in this segment.
On the contrary, immunological disorders, including autoimmune diseases and inflammatory conditions, represent another significant therapy area for protein therapeutics. Monoclonal antibodies and other protein-based drugs modulate the immune system and target specific disease pathways. The growing incidence of immunological disorders and the expanding range of approved protein therapeutics for these conditions are driving the market.
In addition, cancer remains one of the primary drivers of the market. Protein-based therapies, including monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors, have revolutionized cancer treatment. The increasing incidence of cancer globally, coupled with the development of targeted therapies and immunotherapies, is propelling the growth of the market in oncology.
Enzymatic and Regulatory Activity
Special Targeting Activity
Vaccines
Protein Diagnostics
A detailed breakup and analysis of the market based on the function have also been provided in the report. This includes enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics.
Protein therapeutics with enzymatic and regulatory activity are vital in modulating biological processes and metabolic pathways. These proteins act as enzymes, receptors, or signaling molecules, offering therapeutic benefits in various diseases. The development of novel protein therapeutics with specific enzymatic or regulatory functions drives market growth in this segment.
Furthermore, special targeting activity refers to protein therapeutics targeting certain cells, tissues, or molecular targets. Monoclonal antibodies and antibody-drug conjugates are examples of protein therapeutics with special targeting activity. They can precisely recognize and bind to specific molecules or cells, providing highly targeted therapies. The increasing demand for targeted treatments in conditions such as cancer and autoimmune diseases fuels the growth of protein therapeutics in this segment.
Moreover, vaccines are another significant segment in the market. Protein-based vaccines utilize specific proteins or peptides to stimulate an immune response and confer immunity against infectious diseases. The global focus on vaccination programs, the emergence of new infectious diseases, and the need for improved vaccine technologies drive market growth in this segment.
Besides, protein diagnostics involves using proteins or protein-based assays for diagnostic purposes. These diagnostics can detect specific proteins or biomarkers associated with diseases, aiding in early detection, disease monitoring, and personalized treatment. The growing demand for accurate and reliable diagnostic tools fuels the growth of protein diagnostics and contributes to the overall market.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest protein therapeutics market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
North America, particularly the United States, holds a significant market share. The region benefits from advanced healthcare infrastructure, a strong presence of biopharmaceutical companies, and robust research and development activities. The presence of key players and extensive investments in protein therapeutics research contribute to market growth in North America. Additionally, the high prevalence of chronic diseases, a large aging population, and favorable reimbursement policies further drive the market in the region.
On the other hand, Asia Pacific is emerging as a rapidly growing market. The region has a large population base, increasing healthcare expenditure, and a rising prevalence of chronic diseases. Countries such as China, Japan, and India are witnessing substantial growth in the biopharmaceutical industry and investing in research and development. Moreover, the increasing awareness of personalized medicine and growing demand for cost-effective treatment options are driving the adoption of protein therapeutics in Asia Pacific.
Top companies are investing heavily in scientific research to identify new therapeutic targets and develop protein-based drugs with enhanced efficacy and safety profiles. They leverage their protein engineering, molecular biology, and biotechnology expertise to design and optimize therapeutic proteins. Furthermore, these companies establish strategic collaborations with academic institutions, research organizations, and other pharmaceutical companies to access new technologies, expand their pipelines, and accelerate development. Collaborations enable the exchange of knowledge, resources, and expertise, fostering innovation and driving the market. Moreover, successful commercialization strategies play a vital role in driving market growth. These companies employ robust marketing and sales efforts to promote and distribute their products to healthcare providers and patients worldwide. They conduct extensive clinical trials, generate compelling clinical data, and obtain regulatory approvals to ensure market access. Additionally, the top companies continuously invest in manufacturing capabilities and quality control systems to meet the growing demand and ensure a consistent supply of their products. This commitment to manufacturing excellence helps them meet the needs of patients, healthcare providers, and payers, further driving the market growth.
Amgen Inc.
Abbott Laboratories
Abbvie Inc.
Baxter International Inc.
Biogen Inc.
Csl Behring L.L.C. (CSL Limited)
Eli Lilly and Company
F. Hoffmann-La Roche AG (Roche Holding AG)
Johnson & Johnson
Merck & Co. Inc.
Novo Nordisk A/S (Novo Holdings A/S)
Pfizer Inc.
In 2020, Amgen Inc. entered into a collaboration with Adaptive Biotechnologies to develop and commercialize fully human-neutralizing antibodies targeting SARS-CoV-2, the virus that causes COVID-19.
In 2021, Abbott Laboratories received FDA clearance for their Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, a minimally invasive therapy for patients with severe mitral regurgitation.
In 2020, AbbVie Inc. acquired Allergan, a pharmaceutical company known for its portfolio of aesthetic and therapeutic products, including Botox.